<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02320409</url>
  </required_header>
  <id_info>
    <org_study_id>2014-012-00CH2</org_study_id>
    <nct_id>NCT02320409</nct_id>
  </id_info>
  <brief_title>A Food Effect Phase I Study of the Sulfatinib in Healthy Subjects (HMPL-012)</brief_title>
  <official_title>A Food Effect Phase I Study of the Sulfatinib in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hutchison Medipharma Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hutchison Medipharma Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate to determine the effect of food on the PK of a&#xD;
      single dose of 250 mg Sulfatinib and its metabolites in healthy subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate to determine the effect of food on the PK(&#xD;
      pharmacokinetics) of a single dose of 250 mg Sulfatinib and its metabolites in healthy&#xD;
      subjects and to assess the safety and tolerability of single doses of 250mg in healthy&#xD;
      subjects.This study will be an open-label, randomized, two-period, crossover PK food effect&#xD;
      study of Sulfatinib administered orally at 250 mg. Subjects will be screened for eligibility&#xD;
      up to 14 days prior to entry into the study,there will be 2 treatments,2 weeks follow-up.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The following PK parameters will be derived from the plasma concentration-time profile of Sufatinib following administration</measure>
    <time_frame>1-3 days</time_frame>
    <description>Area Under Curve (AUC), both from time zero to time with last observation and from time zero to infinity;;Maximum plasma concentration (Cmax);Time to reach the Cmax (Tmax);elimination half-life</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AE (adverse event) will be summarized by type and severity</measure>
    <time_frame>1 day to the 14 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Sulfatinib ,after general diet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>First cycle, single oral Sulfatinib after general diet intake; Second cycle, Sulfatinib before general diet intake.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sulfatinib, before general diet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>First cycle, single oral Sulfatinib before general diet intake;Second cycle,single oral Sulfatinib after general diet intake</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sulfatinib</intervention_name>
    <description>250mg Sulfatinib ,single dose,oral</description>
    <arm_group_label>Sulfatinib ,after general diet</arm_group_label>
    <arm_group_label>Sulfatinib, before general diet</arm_group_label>
    <other_name>HMPL-012</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males , between 18 and 55 years of age, inclusive.&#xD;
&#xD;
          -  Body mass index (BMI) within the range of 20 to 30 kg/m2, inclusive.&#xD;
&#xD;
          -  In good health, determined by no clinically significant findings from medical history,&#xD;
             physical examination, 12-lead ECG, and vital signs.&#xD;
&#xD;
          -  Adequate hepatic, renal, heart, and hematologic functions&#xD;
&#xD;
          -  Male subjects who are either sterile or agree to use and get the agreement of their&#xD;
             sexual partners to use , during the period from informed consent until 90 days&#xD;
             following Study Completion, 1 of the following approved methods of contraception:&#xD;
             condom, use by female sexual partner of an intrauterine device, contraceptive sponge,&#xD;
             diaphragm, or use of a cervical cap; or an oral, implantable, transdermal, injectable&#xD;
             contraceptives or other contraceptive measures.&#xD;
&#xD;
          -  Able to comprehend and willing to sign an informed consent form (ICF).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  disease history or clinical manifestation of any significant metabolic/endocrine,&#xD;
             allergic, dermatological, hepatic, renal, hematological, pulmonary, immune,&#xD;
             cardiovascular, gastrointestinal, genitourinary, neurological, or psychiatric&#xD;
             disorder(as determined by the Investigator).&#xD;
&#xD;
          -  History of significant hypersensitivity, intolerance, or allergy to any drug compound,&#xD;
             food, or other substance, unless approved by the Investigator.&#xD;
&#xD;
          -  serum total bilirubin&gt;34.2 umol/L；&#xD;
&#xD;
          -  serum albumin&lt;35 g/L；&#xD;
&#xD;
          -  GFR &lt; 80 mL/min/1.73m2. Algorithm: GFR (mL/min/1.73m2) =186 × (SCr)-1.154 ×&#xD;
             (Age)-0.203, Scr= serum creatinine, mg/dL；&#xD;
&#xD;
          -  Blood pressure greater than 140/90.&#xD;
&#xD;
          -  History or presence of an abnormal ECG, which, in the Investigator's opinion, is&#xD;
             clinically significant.&#xD;
&#xD;
          -  Smoking more than 10 cigarettes daily without intention to quit smoking during study.&#xD;
&#xD;
          -  History of stomach or intestinal surgery, nephrectomy, cholecystectomy or resection&#xD;
             that would potentially alter absorption and/or excretion of orally administered drugs&#xD;
             as determined by the investigator (appendectomy and/or hernia repair may be allowed).&#xD;
&#xD;
          -  Significant allergy history(eg. drug allergy); acute allergic rhinitis or food allergy&#xD;
             within 2 weeks prior to informed consent.&#xD;
&#xD;
          -  Donation of blood or plasma ≥ 500 mL from 30 days prior to informed consent, or of&#xD;
             blood or plasma ≥250 mL from 2 weeks prior to informed consent.&#xD;
&#xD;
          -  Receipt of blood products within 2 months prior to informed consent;&#xD;
&#xD;
          -  Poor peripheral venous access.&#xD;
&#xD;
          -  Participants who are positive for hepatitis B surface antigen (HBs antigen) or&#xD;
             hepatitis B core antibody , hepatitis C virus (HCV) antibody;&#xD;
&#xD;
          -  Participants who are human immunodeficiency virus (HIV)-positive;&#xD;
&#xD;
          -  Diagnosis of alcoholism or drug addiction within 1 year prior to informed consent.&#xD;
&#xD;
          -  Participation in any other investigational drug study in which receipt of an&#xD;
             investigational study drug occurred within 5 half-lives or 28 days, whichever is&#xD;
             longer prior to informed consent.&#xD;
&#xD;
          -  Use of any prescription medications or products within 14 days prior to informed&#xD;
             consent.&#xD;
&#xD;
          -  Use of any over-the-counter (OTC), non-prescription preparations (including vitamins,&#xD;
             minerals, and phytotherapeutic, herbal,) within 7 days prior to informed consent.&#xD;
&#xD;
          -  Use of alcohol-, grapefruit-, Seville orange-, or caffeine-containing foods, juices,&#xD;
             or beverages within 72 hours prior to informed consent.&#xD;
&#xD;
          -  Use of known hepatic or renal clearance altering agents (eg, erythromycin, cimetidine,&#xD;
             barbiturates, phenothiazines, or herbal/plant derived preparations such as St. John's&#xD;
             Wort, etc.) for a period of 60 days prior to first dose;&#xD;
&#xD;
          -  principal investigator, investigator, pharmacist, Clinical Research Coordinator or any&#xD;
             personnel related to this study.&#xD;
&#xD;
          -  Any acute or chronic condition that, in the opinion of the Investigator, would limit&#xD;
             the subject's ability to complete and/or participate in this clinical study.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chen Yu, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Xuhui Center Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shanghai Xuhui Central Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200031</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>December 16, 2014</study_first_submitted>
  <study_first_submitted_qc>December 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 19, 2014</study_first_posted>
  <last_update_submitted>May 6, 2020</last_update_submitted>
  <last_update_submitted_qc>May 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Subjects</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

